COURAGE Suggests Stents Do Not Benefit Stable Coronary Disease Patients
This article was originally published in The Gray Sheet
Executive SummaryResults of the highly anticipated COURAGE trial challenge the widespread assumption that stents improve outcomes in patients with stable coronary disease, but several observers believe the findings' impact on the stent market will be modest
You may also be interested in...
Percutaneous coronary intervention with medical therapy does not reduce the risk of death, myocardial infarction or the need for unplanned revascularization procedures compared with medical therapy alone, a meta-analysis of five studies confirms.
With a total market potential estimated in the multibillion-dollar range, the drug-coated balloon opportunity is attracting a growing list of competitors, including several leading multinational cardiovascular device companies that have entered the space via recent acquisitions. DCBs still need to prove their worth in large, long-term clinical trials, but the ultimate proving point for DCBs could center on cost: if they can offer an effective treatment option that is significantly less expensive than existing devices, DCBs may provide a compelling economic argument.
The prospective medical device tax, the continuing decline of venture investing, pricing challenges, austerity measures in Europe, and other headwinds continued to push against the medtech industry in 2012. But emerging clinical and geographic markets, along with an active M&A market, provided the industry with some momentum.